Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:CLRB NASDAQ:HOOK NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/ACLRBCellectar Biosciences$3.18+12.4%$2.92$2.43▼$20.60$12M0.4322,906 shs54.48 million shsHOOKHOOKIPA Pharma$1.19+0.8%$1.09$0.81▼$1.77$14.67M0.8411,190 shs6,162 shsMYNZMainz Biomed$0.40-2.6%$0.61$0.55▼$4.43$3.62M0.31371,589 shs354,476 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%0.00%-76.32%CLRBCellectar Biosciences+18.22%+24.22%+24.71%+6.35%-60.17%HOOKHOOKIPA Pharma+0.42%+3.48%+3.48%+13.33%-7.03%MYNZMainz Biomed-2.58%-25.90%-12.68%-62.96%-85.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/ACLRBCellectar Biosciences$3.18+12.4%$2.92$2.43▼$20.60$12M0.4322,906 shs54.48 million shsHOOKHOOKIPA Pharma$1.19+0.8%$1.09$0.81▼$1.77$14.67M0.8411,190 shs6,162 shsMYNZMainz Biomed$0.40-2.6%$0.61$0.55▼$4.43$3.62M0.31371,589 shs354,476 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%0.00%-76.32%CLRBCellectar Biosciences+18.22%+24.22%+24.71%+6.35%-60.17%HOOKHOOKIPA Pharma+0.42%+3.48%+3.48%+13.33%-7.03%MYNZMainz Biomed-2.58%-25.90%-12.68%-62.96%-85.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 1.75Reduce$1.251,113.59% UpsideCLRBCellectar Biosciences 2.33Hold$11.00245.91% UpsideHOOKHOOKIPA Pharma 0.00N/AN/AN/AMYNZMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest MYNZ, HOOK, CLRB, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026CLRBCellectar Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/20/2026CLRBCellectar Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/10/2026CLRBCellectar Biosciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy3/6/2026MYNZMainz Biomed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21CLRBCellectar BiosciencesN/AN/AN/AN/A$1.89 per shareN/AHOOKHOOKIPA Pharma$9.35M1.57N/AN/A$4.25 per share0.28MYNZMainz Biomed$659.94K5.49N/AN/A$2.61 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/ACLRBCellectar Biosciences-$21.79M-$9.53N/AN/AN/AN/A-298.05%-144.59%5/12/2026 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%5/7/2026 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest MYNZ, HOOK, CLRB, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CLRBCellectar Biosciences-$1.8850N/AN/AN/A$8.00 millionN/A3/4/2026Q4 2025CLRBCellectar Biosciences-$1.19-$0.53+$0.66-$0.53N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.960.96CLRBCellectar BiosciencesN/A2.962.96HOOKHOOKIPA PharmaN/A3.613.61MYNZMainz Biomed0.440.520.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CLRBCellectar Biosciences16.41%HOOKHOOKIPA Pharma63.88%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%CLRBCellectar Biosciences5.04%HOOKHOOKIPA Pharma3.30%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableCLRBCellectar Biosciences104.24 million4.03 millionNo DataHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableMYNZ, HOOK, CLRB, and APLT HeadlinesRecent News About These CompaniesMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deStrategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comMainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf BauchspeicheldrüsenkrebsFebruary 17, 2026 | de.investing.comMainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer programFebruary 17, 2026 | msn.comMainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateFebruary 17, 2026 | finance.yahoo.comMainz Biomed nimmt 2,15 Mio. US-Dollar über At-the-Market-Platzierung ein/nFebruary 10, 2026 | de.investing.comMainz Biomed Aktie: Neue Studiendaten vorausFebruary 7, 2026 | stock-world.deSMainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingJanuary 14, 2026 | globenewswire.comMainz Biomed expects to complete eAArly DETECT 2 study in 2026January 6, 2026 | msn.comMainz Biomed Provides Review of 2025 HighlightsJanuary 5, 2026 | markets.businessinsider.comMainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening ProgramJanuary 5, 2026 | quiverquant.comQ2 Small-Cap Biotechs That Could Reward Patient Investors (MYNZ)...December 12, 2025 | marketbeat.comMainz Biomed files $150M mixed securities shelfDecember 5, 2025 | msn.comMainz Biomed announces ColoAlert added to portfolio of DoctorBoxDecember 2, 2025 | msn.comDoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioDecember 2, 2025 | markets.businessinsider.comMainz BioMed NV: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | finanznachrichten.deMainz Biomed, OncoVanguard8 agree to bring ColoAlert to South AmericaNovember 18, 2025 | msn.comMainz Biomed Signs Memorandum of Understanding with OncoVanguard8 to Launch ColoAlert® Colorectal Cancer Screening in South AmericaNovember 18, 2025 | quiverquant.comQMainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, HOOK, CLRB, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 05/4/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Cellectar Biosciences NASDAQ:CLRB$3.18 +0.35 (+12.37%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$3.01 -0.17 (-5.31%) As of 05/5/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.HOOKIPA Pharma NASDAQ:HOOK$1.19 +0.01 (+0.85%) As of 05/5/2026 03:59 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Mainz Biomed NASDAQ:MYNZ$0.40 -0.01 (-2.58%) As of 05/4/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
